TRIAL DATA
Short-course immunotherapy drives deep responses in resectable colon cancerIn the phase 2 UNICORN trial, neoadjuvant botensilimab plus balstilimab achieved major pathological responses in 36% of pMMR and 100% of dMMR colon cancer patients, with no recurrences reported at data cutoff. (Targeted Oncology)